Cancer vaccines using dendritic cells (DCs) have been shown to induce antitumor immunity
and have recently been applied to non-immunogenic cancers, such as pancreatic cancer. In …

Tumor cells harbor unique genetic mutations, which lead to the generation of
immunologically foreign antigenic peptide repertoire with the potential to induce individual …

Introduction Once metastasis has occurred, the possibility of completely curing breast cancer
is unlikely, particularly for the 30 to 40% of cancers overexpressing the gene for HER2/neu …

Our laboratory has created an Ad-sig-TAA/ecdCD40L vaccine platform designed to activate
dendritic cells (DCs). Two subcutaneous (sc) injections of the TAA/ecdCD40L protein …

Delivery of antigens to antigen presenting cells (APCs) is a key issue for developing
effective cancer vaccines. Controlling the tissue distribution of antigens can increase antigen …

In an effort to enhance the potency of DNA vaccines, we have developed a new strategy to
increase antigen presentation by dendritic cells, one that results in markedly improved …

Almost 60 years ago, the pioneering work of George Klein and others showed that cancers
could be made targets for the immune system. Identification of the tumor targets, known as …

HSP110 is a large molecular weight heat shock protein highly capable of chaperoning large
proteins. When chaperoning tumour antigens, HSP110 is capable of eliciting effective anti …

Using syngeneic murine tumor models established in immunocompetent hosts, we showed
that cancer stem cells are immunogenic and can be selectively targeted by dendritic cell …

Immune-based therapies for cancer are generating substantial interest because of the
success of immune checkpoint inhibitors. This study aimed to enhance anticancer immunity …